A CSI-based Human Activity Recognition using Canny Edge Detector

Human Activity Recognition (HAR) is one of the hot topics in the field of human-computer interaction. It has a wide variety of applications in different tasks such as health rehabilitation, smart houses, smart grids, robotics, and human action prediction. HAR can be carried out through different approaches such as vision-based, sensor-based, radar-based, and Wi-Fi-based. Due to the ubiquitous and easyto-deploy characteristic of Wi-Fi devices, Wi-Fi-based HAR has gained the interest of both academia and industry in recent years.WiFi-based HAR can be implemented by two channel metrics: Channel State Information (CSI) and Received Signal Strength Indicator (RSSI). Recently, converting the CSI data to images has led to increasing the accuracy level of activity prediction. However, none of the previous research has focused on extracting the features of converted images using image-processing techniques. In this study, we investigate three available datasets, gathered using CSI property, and took advantage of Deep Learning (DL), with convolutional layers and edge detection technique to increase overall system accuracy. The canny edge detector extracts the most important features of the image, and giving it to the DL model empowers the prediction of activities. In all three datasets, we witnessed an improvement of 5%, 27%, and 37% in terms of accuracy

Therapeutic Antibody‐Based Drugs in the Treatment of Human Inflammatory Disorders

Inflammation causes debilitating human conditions and older treatments rely on global immunosuppression that non‐specifically alleviates symptoms. Currently, several monoclonal antibodies (mAbs) are available that specifically block pro‐inflammatory cytokines. These include mAbs specific to tumour necrosis factor (TNF), interleukin (IL)‐1β, IL‐6, IL‐17 and IL‐12/IL‐23. The chapter summarises the key elements in human inflammatory disease conditions, including various forms of arthritis, psoriasis, Crohn\u27s disease and ulcerative colitis, plus pyrin‐associated inflammatory syndromes and periodic fevers, to explain the benefit of cytokine neutralisation through mAb‐type reagents. The chapter reviews the efficacy and safety of the current repertoire of anti‐cytokine/cytokine receptor mAbs. It also discusses the known side effects and adverse events that are sometimes associated with systemic blockade of cytokines in vivo, and concludes that the accumulating knowledge of treatment failures can reveal unappreciated aspects of cytokine biology and even new treatment opportunities. The chapter includes mention of the rapidly expanding cohort of biosimilar mAbs and the mAbs to IL‐4, IL‐5 and IL‐13 that are now emerging, in addition to the need for treatments for disorders that remain refractory to the current repertoire of anti‐cytokine mAbs and conventional treatments. Thus, here we summarise the current status of anti‐cytokine mAbs for human inflammatory diseases

Therapeutic Antibody-Based Drugs in the Treatment of Human Inflammatory Disorders

Inflammation causes debilitating human conditions and older treatments rely on global immunosuppression that non‐specifically alleviates symptoms. Currently, several monoclonal antibodies (mAbs) are available that specifically block pro‐inflammatory cytokines. These include mAbs specific to tumour necrosis factor (TNF), interleukin (IL)‐1β, IL‐6, IL‐17 and IL‐12/IL‐23. The chapter summarises the key elements in human inflammatory disease conditions, including various forms of arthritis, psoriasis, Crohn's disease and ulcerative colitis, plus pyrin‐associated inflammatory syndromes and periodic fevers, to explain the benefit of cytokine neutralisation through mAb‐type reagents. The chapter reviews the efficacy and safety of the current repertoire of anti‐cytokine/cytokine receptor mAbs. It also discusses the known side effects and adverse events that are sometimes associated with systemic blockade of cytokines in vivo, and concludes that the accumulating knowledge of treatment failures can reveal unappreciated aspects of cytokine biology and even new treatment opportunities. The chapter includes mention of the rapidly expanding cohort of biosimilar mAbs and the mAbs to IL‐4, IL‐5 and IL‐13 that are now emerging, in addition to the need for treatments for disorders that remain refractory to the current repertoire of anti‐cytokine mAbs and conventional treatments. Thus, here we summarise the current status of anti‐cytokine mAbs for human inflammatory diseases